754P Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study
| Autor: | O'Cearbhaill, R.E., Moore, K.N., Yeku, O., Liu, J.F., Bouberhan, S., Hamilton, E.P., Hou, J.Y., Van Nieuwenhuysen, E., Papadimitriou, K., Yoo, S-Y., Govindraj, S., Brouwer-Visser, J., Peterman, M., Schmidt, T., Barnes, B., Madia, P., Zhu, M., Uldrick, T.S., Miller, E.A., O'Malley, D. |
|---|---|
| Zdroj: | In Annals of Oncology October 2023 34 Supplement 2:S516-S517 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|